An international, prospective, multicentre, observational study to evaluate the long-term safety profile of alemtuzumab treatment in patients with relapsing-remitting multiple-sclerosis (RRMS) in real life

Trial Profile

An international, prospective, multicentre, observational study to evaluate the long-term safety profile of alemtuzumab treatment in patients with relapsing-remitting multiple-sclerosis (RRMS) in real life

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms PASS
  • Most Recent Events

    • 26 Jul 2017 New trial record
    • 27 Jun 2017 Trial design of the study presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top